Using exome- or genome-wide sequencing strategies and TCGA databases, various somatic mutations and deletions of UTX have been found in several human cancers, with a prevalence of 24.24% in bladder cancer, 10% in prostate cancer, and 1.85% in esophageal cancer [20]. This evidence concerns the gene KDM6A and cancer.